A LONG-TERM SAFETY STUDY OF MARALIXIBAT, AN APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN SUBJECTS WHO PREVIOUSLY PARTICIPATED IN A MARALIXIBAT STUDY

Registry ID

MRX-800

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

MIRUM PHARMACEUTICALS, INC

Start date

2020-05-12

Completion date

2024-09-04

Last update

2020-02-14

Conditions

• PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
• CHOLESTATIC LIVER DISEASE
• ALAGILLE SYNDROME

Related clinical trials

• A MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME

View on source registry